Physician profile
Thomas A Self
NPI 1881627107
$722.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $189.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $188.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $101.84 | 2020 | |
| Novo Nordisk INC | $88.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.74 | 2019 | |
| Amgen INC. | $45.88 | 2019 | |
| Pfizer INC. | $43.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $28.49 | 2019 | |
| Horizon Therapeutics Plc | $27.91 | 2019 | |
| Abbott Laboratories | $26.56 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.64 | 2019 | |
| Allergan, INC. | $24.01 | 2019 | |
| Dynavax Technologies Corporation | $21.81 | 2019 | |
| Merck Sharp & Dohme LLC | $17.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.